Business Description
89bio Inc
NAICS : 325412
SIC : 2834
ISIN : US2825591033
Share Class Description:
ETNB: Ordinary SharesCompare
Compare
Traded in other countries / regions
ETNB.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2019-11-11Description
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.71 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 15.1 | |||||
| 3-Year EPS without NRI Growth Rate | 13.4 | |||||
| 3-Year FCF Growth Rate | 14.3 | |||||
| 3-Year Book Growth Rate | -17.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 15.76 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.42 | |||||
| 9-Day RSI | 32.41 | |||||
| 14-Day RSI | 41.33 | |||||
| 3-1 Month Momentum % | 6.41 | |||||
| 6-1 Month Momentum % | 5.81 | |||||
| 12-1 Month Momentum % | -26.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.18 | |||||
| Quick Ratio | 12.18 | |||||
| Cash Ratio | 12.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -67.3 | |||||
| Shareholder Yield % | -14.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -78.41 | |||||
| ROA % | -68.16 | |||||
| ROIC % | -1625.51 | |||||
| 3-Year ROIIC % | -1752.96 | |||||
| ROC (Joel Greenblatt) % | -21151.42 | |||||
| ROCE % | -71.99 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.6 | |||||
| Price-to-Tangible-Book | 2.6 | |||||
| EV-to-EBIT | -2.48 | |||||
| EV-to-Forward-EBIT | -2.42 | |||||
| EV-to-EBITDA | -2.48 | |||||
| EV-to-Forward-EBITDA | -2.47 | |||||
| EV-to-FCF | -3.37 | |||||
| Price-to-Net-Current-Asset-Value | 2.87 | |||||
| Price-to-Net-Cash | 2.87 | |||||
| Earnings Yield (Greenblatt) % | -40.32 | |||||
| FCF Yield % | -29.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ETNB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
89bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.43 | ||
| Beta | 0.62 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 0.96 | ||
| Volatility % | 51.71 | ||
| 14-Day RSI | 41.33 | ||
| 14-Day ATR ($) | 0.699569 | ||
| 20-Day SMA ($) | 10.4615 | ||
| 12-1 Month Momentum % | -26.39 | ||
| 52-Week Range ($) | 5.9857 - 16.63 | ||
| Shares Outstanding (Mil) | 145.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
89bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
89bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
89bio Inc Frequently Asked Questions
What is 89bio Inc(ETNB)'s stock price today?
The current price of ETNB is $8.67. The 52 week high of ETNB is $16.63 and 52 week low is $5.99.
When is next earnings date of 89bio Inc(ETNB)?
The next earnings date of 89bio Inc(ETNB) is 2025-05-09 Est..
Does 89bio Inc(ETNB) pay dividends? If so, how much?
89bio Inc(ETNB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers